Cochlear Limited provides implantable hearing solutions for adults and children worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$216.88|
|52 Week High||AU$176.68|
|52 Week Low||AU$257.76|
|1 Month Change||-8.98%|
|3 Month Change||-10.13%|
|1 Year Change||1.73%|
|3 Year Change||18.17%|
|5 Year Change||60.53%|
|Change since IPO||7,251.86%|
Recent News & Updates
This Is Why We Think Cochlear Limited's (ASX:COH) CEO Might Get A Pay Rise Approved By Shareholders
Shareholders will be pleased by the robust performance of Cochlear Limited ( ASX:COH ) recently and this will be kept...
A Look At The Fair Value Of Cochlear Limited (ASX:COH)
Today we will run through one way of estimating the intrinsic value of Cochlear Limited ( ASX:COH ) by taking the...
|COH||AU Medical Equipment||AU Market|
Return vs Industry: COH exceeded the Australian Medical Equipment industry which returned -4.9% over the past year.
Return vs Market: COH underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: COH is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: COH's weekly volatility (4%) has been stable over the past year.
About the Company
Cochlear Limited provides implantable hearing solutions for adults and children worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company was founded in 1981 and is headquartered in Sydney, Australia.
Cochlear Fundamentals Summary
|COH fundamental statistics|
Is COH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|COH income statement (TTM)|
|Cost of Revenue||AU$410.20m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Feb 22, 2022
|Earnings per share (EPS)||4.96|
|Net Profit Margin||21.80%|
How did COH perform over the long term?See historical performance and comparison
1.3%Current Dividend Yield
Is Cochlear undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: COH (A$216.88) is trading above our estimate of fair value (A$183.03)
Significantly Below Fair Value: COH is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: COH is poor value based on its PE Ratio (43.7x) compared to the Australian Medical Equipment industry average (13.8x).
PE vs Market: COH is poor value based on its PE Ratio (43.7x) compared to the Australian market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: COH is poor value based on its PEG Ratio (5.5x)
Price to Book Ratio
PB vs Industry: COH is overvalued based on its PB Ratio (8.4x) compared to the AU Medical Equipment industry average (4.5x).
How is Cochlear forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: COH's forecast earnings growth (7.9% per year) is above the savings rate (1.9%).
Earnings vs Market: COH's earnings (7.9% per year) are forecast to grow slower than the Australian market (11.8% per year).
High Growth Earnings: COH's earnings are forecast to grow, but not significantly.
Revenue vs Market: COH's revenue (9.4% per year) is forecast to grow faster than the Australian market (5.5% per year).
High Growth Revenue: COH's revenue (9.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: COH's Return on Equity is forecast to be low in 3 years time (18.4%).
How has Cochlear performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: COH has high quality earnings.
Growing Profit Margin: COH became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: COH's earnings have declined by 20.2% per year over the past 5 years.
Accelerating Growth: COH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: COH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: COH's Return on Equity (19.2%) is considered low.
How is Cochlear's financial position?
Financial Position Analysis
Short Term Liabilities: COH's short term assets (A$1.2B) exceed its short term liabilities (A$402.5M).
Long Term Liabilities: COH's short term assets (A$1.2B) exceed its long term liabilities (A$334.0M).
Debt to Equity History and Analysis
Debt Level: COH's debt to equity ratio (2.6%) is considered satisfactory.
Reducing Debt: COH's debt to equity ratio has reduced from 43% to 2.6% over the past 5 years.
Debt Coverage: COH's debt is well covered by operating cash flow (602.9%).
Interest Coverage: COH's interest payments on its debt are well covered by EBIT (41x coverage).
What is Cochlear current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: COH's dividend (1.29%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.27%).
High Dividend: COH's dividend (1.29%) is low compared to the top 25% of dividend payers in the Australian market (5.32%).
Stability and Growth of Payments
Stable Dividend: COH's dividend payments have been volatile in the past 10 years.
Growing Dividend: COH's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (51.3%), COH's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: COH's dividends in 3 years are forecast to be covered by earnings (72.9% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dig Howitt (54 yo)
Mr. Diggory William Howitt, also known as Dig, BE (Hons), MBA has been President of Cochlear Limited since July 31, 2017 and its Chief Executive Officer and Managing Director since January 3, 2018. Mr. How...
CEO Compensation Analysis
Compensation vs Market: Dig's total compensation ($USD3.61M) is about average for companies of similar size in the Australian market ($USD3.61M).
Compensation vs Earnings: Dig's compensation has been consistent with company performance over the past year.
Experienced Management: COH's management team is seasoned and experienced (5 years average tenure).
Experienced Board: COH's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: COH insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cochlear Limited's employee growth, exchange listings and data sources
- Name: Cochlear Limited
- Ticker: COH
- Exchange: ASX
- Founded: 1981
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$14.265b
- Shares outstanding: 65.78m
- Website: https://www.cochlear.com
Number of Employees
- Cochlear Limited
- 1 University Avenue
- Macquarie University
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/17 07:04|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.